Patents by Inventor Toshiaki Akira
Toshiaki Akira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030203354Abstract: A method for screening an apoptosis inhibitor characterized by screening a candidate via an effect on PGT. A cell protecting agent containing as the active ingredient a substance which can be incorporated into cells via prostaglandin transporter (PGT); and a screening method therefor comprising measuring the uptake into cells via PGT. An apoptosis inducer containing as the active ingredient a substance having a PGT inhibitory effect; and a screening method therefor comprising measuring the ability to induce apoptosis of cells with the expression of PGT. Because of having a cell apoptosis inhibitory effect, the cell protecting agent is useful as a nerve cell apoptosis inhibitor, a nerve cell protecting agent, etc. and applicable to the prevention or treatment of nervous diseases, etc. The apoptosis inducer is useful in preventing and/or treating diseases in association with cell proliferation such as tumor, etc.Type: ApplicationFiled: June 11, 2003Publication date: October 30, 2003Applicant: MITSUBISHI PHARMA CORPORATIONInventors: Tooru Kawamura, Satoshi Horie, Toshiaki Akira, Norifumi Nakamura, Tomoyuki Maruyama, Kazutaka Hayashi
-
Publication number: 20030032793Abstract: It is the matter to be solved by the present invention to provide mRNA coding for the PGT of a human brain type and to provide a polynucleotide coding for the PGT of a human brain type prepared using the said mRNA as a template. There are provided mRNA coding for the PGT of a human brain type and having a molecular weight of 38-40 kilodaltons and a polynucleotide being prepared by the use of the said mRNA as a template and having a specific base sequence represented by SEQ ID NO: 2 of the Sequence Listing.Type: ApplicationFiled: April 4, 2002Publication date: February 13, 2003Inventors: Toru Kawamura, Satoshi Horie, Toshiaki Akira, Shusei Uno
-
Publication number: 20020127228Abstract: A method for screening an apoptosis inhibitor characterized by screening a candidate via an effect on PGT. A cell protecting agent containing as the active ingredient a substance which can be incorporated into cells via prostaglandin transporter (PGT); and a screening method therefor comprising measuring the uptake into cells via PGT. An apoptosis inducer containing as the active ingredient a substance having a PGT inhibitory effect; and a screening method therefor comprising measuring the ability to induce apoptosis of cells with the expression of PGT. Because of having a cell apoptosis inhibitory effect, the cell protecting agent is useful as a nerve cell apoptosis inhibitor, a nerve cell protecting agent, etc. and applicable to the prevention or treatment of nervous diseases, etc. The apoptosis inducer is useful in preventing and/or treating diseases in association with cell proliferation such as tumor, etc.Type: ApplicationFiled: June 4, 2001Publication date: September 12, 2002Applicant: WELFIDE CORPORATIONInventors: Tooru Kawamura, Satoshi Horie, Toshiaki Akira, Norifumi Nakamura, Tomoyuki Maruyama, Kazutaka Hayashi
-
Patent number: 6369061Abstract: A therapeutic agent for spinal canal stenosis is provided, which contains a pyridazinone compound of the formula (I) wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl, X is a halogen atom, a cyano or a hydrogen atom, Y is a halogen atom, a trifluoromethyl or a hydrogen atom, and A is a C1-C8 alkylene optionally substituted with a hydroxyl, or its pharmacologically acceptable salt.Type: GrantFiled: March 21, 2001Date of Patent: April 9, 2002Assignees: Mitsubishi Pharma Corporation, Nissan Chemical Industries, Ltd.Inventors: Tomoyuki Maruyama, Toru Kawamura, Toshiaki Akira, Hideaki Kido, Norifumi Nakamura
-
Patent number: 5888964Abstract: A method for increasing the placental blood flow, which comprises administering a human-originated antithrombin-III. The human-originated antithrombin-III increases the placental blood flow in mammals and particularly improves intrauterine growth retardation caused by a decreased blood flow. The method is highly safe to the mother and fetus, since it uses human-originated AT-III as an active ingredient, thereby enabling effective and safe treatment of intrauterine growth retardation (IUGR) and the like.Type: GrantFiled: April 24, 1996Date of Patent: March 30, 1999Assignees: The Green Cross Corporation, Hoechst Japan LimitedInventors: Hiroshi Shinyama, Toshiaki Akira, Takeshi Uchida, Masahiro Watanabe
-
Patent number: 5053498Abstract: A therapeutic and prophylactic agent for peptic ulcers which contains as an active ingredient a compound of the general formula (I): ##STR1## wherein R.sub.1 represents hydrogen or .dbd.O; R.sub.2 represents hydrogen or --OR.sub.5 ; R.sub.3 represents hydrogen or --OR.sub.5 ; R.sub.4 represents --OR.sub.7 in the case of the absence of double bond; R.sub.5, R.sub.6 and R.sub.7 each represents hydrogen or an organic residue;X represents group (A);.dbd.C.dbd.CH--COR.sub.8 (A)or group (B): ##STR2## wherein R.sub.8 represents alkyl, and R.sub.9 and R.sub.10 each represents hydrogen or an organic residue; with the proviso that when X represents group (A), then R.sub.1 and R.sub.3 both represent hydrogen, R.sub.2 represents --OR.sub.5, R.sub.4 represents OR.sub.7 and the bond between the carbon atom to which X is attached and the carbon atom to which R.sub.4 is attached is a single bond, and when X represents group (B), then R.sub.1 represents .dbd.O, R.sub.2 represents hydrogen, R.sub.3 represents --OR.sub.Type: GrantFiled: October 16, 1989Date of Patent: October 1, 1991Assignee: Green Cross CorporationInventors: Yusei Shiraga, Chikara Fukaya, Toshiaki Akira, Masakazu Iwai, Kazumasa Yokoyama, Mamoru Tabata, Hiroshi Fukui, Shigeo Tanaka, Yoshiro Iga, Tadakazu Suyama, Kanemichi Okano
-
Patent number: 4983584Abstract: A therapeutic and prophylactic agent for peptic ulcers comprising as an effective ingredient a cyclohexane derivative represented by general formula (I): ##STR1## wherein A represents a group shown by formula, >CH.sub.2, ##STR2## wherein X represents ethynylene, vinylene or ethylene, Y represents oxo or a hydroxy group; R.sup.1, R.sup.3, R.sup.4 and R.sup.5 each represents a hydrogen atom or alkyl; R.sup.2 represents a hydrogen atom, alkyl or a group shown by --OR.sup.8 ;R.sup.6 represents a hydrogen atom, oxo or a group shown by --OR.sup.8 ; and R.sup.7 represents a hydrogen atom or a group shown by --OR.sup.8, wherein R.sup.8 represents a hydrogen atom or an organic residue.Type: GrantFiled: November 23, 1987Date of Patent: January 8, 1991Assignee: Green Cross CorporationInventors: Chikara Fukaya, Hitoshi Yasuda, Toshiaki Akira, Masakazu Iwai, Kanemichi Okano, Kazumasa Yokoyama
-
Patent number: 4888417Abstract: A therapeutic and prophylactic agent for peptic ulcers which contains as an active ingredient a compound of the general formula (I): ##STR1## wherein R.sub.1 represents hydrogen or =O; R.sub.2 represents hydrogen or --OR.sub.5 ; R.sub.3 represents hydrogen or --OR.sub.6 ; R.sub.4 represents --OR.sub.7 in the case of the absence of double bond; R.sub.5, R.sub.6 and R.sub.7 each represents hydrogen or an organic residue;X represents group (A):.dbd.C.dbd.CH--COR.sub.8 (A)or group (B): ##STR2## wherein R.sub.8 represents alkyl, and R.sub.9 and R.sub.10 each represents hydrogen or an organic residue; with the proviso that when X represents group (A), then R.sub.1 and R.sub.3 both represent hydrogen, R.sub.2 represents --OR.sub.5 ; R.sub.4 represents OR.sub.7 and the bond between the carbon atoms to which X is attached and the carbon atom to which R.sub.4 is attached is a single bond, and when X represents group (B), then R.sub.1 represents .dbd.O, R.sub.2 represents hydrogen, R.sub.3 represents --OR.sub.Type: GrantFiled: May 27, 1986Date of Patent: December 19, 1989Assignee: Green Cross CorporationInventors: Yusei Shiraga, Chikara Fukaya, Toshiaki Akira, Masakazu Iwai, Kazumasa Yokoyama, Mamoru Tabata, Hiroshi Fukui, Shigeo Tanaka, Yoshiro Iga, Tadakazu Suyama, Kanemichi Okano
-
Patent number: 4732760Abstract: A curative and preventive agent for ulcers of digestive organs comprising as the main constituent an active component having anti-ulcer activity derived from a hot-water, an alcohol or a water-alcohol mixed solution extract of cassia buds.Type: GrantFiled: June 20, 1986Date of Patent: March 22, 1988Assignee: The Green Cross CorporationInventors: Yoshiro Iga, Kanemichi Okano, Toshiaki Akira